A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
Vima Therapeutics · NCT07304089
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–70 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 100
- US sites recruiting
- 37
- Study start
- February 5, 2026
- Record last updated
- October 22, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.
The main objectives of this clinical trial are to determine the following:
- Does VIM0423 therapy improve dystonia symptoms compared to placebo?
- Is VIM0423 well tolerated in individuals with isolated dystonia? and
- Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?
Being studied: VIM0423; VIM0423 Placebo
Conditions: Dystonia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participant must be male or nonpregnant female between 18 and 70 years of age (inclusive) at Visit 1 (Screening).
- The participant has a clinical diagnosis of isolated dystonia with symptoms consistent with dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee.
- The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria.
- The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S.
Recruiting US locations
Vima Site #033
Birmingham, AL 35233
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #039
Scottsdale, AZ 85251
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #004
Scottsdale, AZ 85258
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #028
Sun City, AZ 85351
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #042
Irvine, CA 92614
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #030
Los Angeles, CA 90048
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #019
Denver, CO 80113
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #009
Gainesville, FL 32608
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #008
Miami, FL 33176
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #031
Orlando, FL 32825
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #005
Atlanta, GA 30329
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #027
Chicago, IL 60611
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #041
Overland Park, KS 66211
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #043
Baltimore, MD 21237
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #007
Olney, MD 20832
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #032
Boston, MA 02215
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #037
East Lansing, MI 48824
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #002
Farmington Hills, MI 48334
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #038
St Louis, MO 63110
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #014
Albuquerque, NM 87106
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #018
New York, NY 10019
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #024
New York, NY 10021
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #036
Rochester, NY 14618
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #040
Fayetteville, NC 28304
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #035
Cincinnati, OH 45212
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #029
Portland, OR 97239
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #020
Philadelphia, PA 19107
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #021
Charleston, SC 29425
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #016
Memphis, TN 38157
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #006
Nashville, TN 37232
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #025
Dallas, TX 75390
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #026
Georgetown, TX 78628
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #012
Houston, TX 77030
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #013
Houston, TX 77030
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #011
Richmond, VA 23233
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #023
Kirkland, WA 98034
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Vima Site #015
Spokane, WA 99202
Site contact: Study Director · 617-430-7027 · clinicaltrials@vimatx.com
Study contacts (from the official record)
- Study Director · 617-430-7027 · Clinicaltrials@vimatx.com